The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Chronic myeloid leukemia (CML) accounts for 2‐3% of leukemias in children under 15 and
9% in adolescents aged 15‐19. The diagnosis and management of CML in children …

This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology
focuses on treatment and management considerations for AYA patients with cancer …

This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology
focuses on considerations for the comprehensive care of AYA patients with cancer …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine
kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a …

The NCCN Guidelines for Chronic Myeloid Leukemia (CML) provide recommendations for
the management of chronic-phase and advanced-phase CML in adult patients. The median …

Cancer during pregnancy is a challenge for multi-and interdisciplinary collaboration due to
the diagnostic, prognostic and therapeutic implications, the need for an integrated …

When imatinib, the first tyrosine kinase inhibitor (TKI) developed for use in chronic
myelogenous leukemia (CML), was approved in 2001, the treatment of this disease was …